BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36966871)

  • 1. Access to Chimeric Antigen Receptor T Cell Clinical Trials in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult Acute Lymphobastic Leukemia Patients.
    Hall AG; Winestone LE; Sullivan EM; Wu Q; Lamble AJ; Walters MC; Aguayo-Hiraldo P; Baez Conde L; Coker TR; Dornsife D; Keating AK; Merino DM; Ramsey B; Park JR; Agrawal AK
    Transplant Cell Ther; 2023 Jun; 29(6):356.e1-356.e7. PubMed ID: 36966871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INSPIRED Symposium Part 1: Clinical Variables Associated with Improved Outcomes for Children and Young Adults treated with Chimeric Antigen Receptor T cells for B cell Acute Lymphoblastic Leukemia.
    Myers RM; Jacoby E; Pulsipher MA; Pasquini MC; Grupp SA; Shah NN; Laetsch TW; Curran KJ; Schultz LM
    Transplant Cell Ther; 2023 Oct; 29(10):598-607. PubMed ID: 37481241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor T Cell Therapy followed by Unrelated Cord Blood Transplantation for the Treatment of Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia in Children and Young Adults: Superior Survival but Relatively High Post-Transplantation Relapse.
    Sun G; Tang B; Wan X; Yao W; Song K; Tu M; Geng L; Qiang P; Wu Y; Zhu L; Wu Y; Liu H; Zhu X; Sun Z
    Transplant Cell Ther; 2022 Feb; 28(2):71.e1-71.e8. PubMed ID: 34839013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes.
    Faruqi AJ; Ligon JA; Borgman P; Steinberg SM; Foley T; Little L; Mackall CL; Lee DW; Fry TJ; Shalabi H; Brudno J; Yates B; Mikkilineni L; Kochenderfer J; Shah NN
    Blood Adv; 2022 Dec; 6(23):6040-6050. PubMed ID: 35939781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
    Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
    Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.
    Shahid S; Ramaswamy K; Flynn J; Mauguen A; Perica K; Park JH; Forlenza CJ; Shukla NN; Steinherz PG; Margossian SP; Boelens JJ; Kernan NA; Curran KJ
    Transplant Cell Ther; 2022 Feb; 28(2):72.e1-72.e8. PubMed ID: 34852305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4
    Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
    Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
    Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
    Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.
    Al Hadidi S; Schinke C; Thanendrarajan S; Zangari M; van Rhee F
    JAMA Netw Open; 2022 Apr; 5(4):e228161. PubMed ID: 35442451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: Two pediatric cases of long-term leukemia-free survival with relapsed acute T-lymphoblastic leukemia treated with donor CD7 CAR-T cells bridging to haploidentical stem cell transplantation.
    Song Y; Liu Z; Wang Q; Gao K; Wu T
    Front Immunol; 2024; 15():1333037. PubMed ID: 38481998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel.
    Ravich JW; Huang S; Zhou Y; Brown P; Pui CH; Inaba H; Cheng C; Gottschalk S; Triplett BM; Bonifant CL; Talleur AC
    Transplant Cell Ther; 2022 Feb; 28(2):73.e1-73.e9. PubMed ID: 34875402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
    Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Lymphoma Remission Confers a Leukemia-Free Survival Advantage.
    Summers C; Wu QV; Annesley C; Bleakley M; Dahlberg A; Narayanaswamy P; Huang W; Voutsinas J; Brand A; Leisenring W; Jensen MC; Park JR; Gardner RA
    Transplant Cell Ther; 2022 Jan; 28(1):21-29. PubMed ID: 34644605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia.
    Myers RM; Dolan J; Teachey DT
    Expert Rev Clin Immunol; 2020 Oct; 16(10):1029-1042. PubMed ID: 32975147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.
    Benjamin R; Graham C; Yallop D; Jozwik A; Mirci-Danicar OC; Lucchini G; Pinner D; Jain N; Kantarjian H; Boissel N; Maus MV; Frigault MJ; Baruchel A; Mohty M; Gianella-Borradori A; Binlich F; Balandraud S; Vitry F; Thomas E; Philippe A; Fouliard S; Dupouy S; Marchiq I; Almena-Carrasco M; Ferry N; Arnould S; Konto C; Veys P; Qasim W;
    Lancet; 2020 Dec; 396(10266):1885-1894. PubMed ID: 33308471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
    Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
    Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Myers RM; Li Y; Barz Leahy A; Barrett DM; Teachey DT; Callahan C; Fasano CC; Rheingold SR; DiNofia A; Wray L; Aplenc R; Baniewicz D; Liu H; Shaw PA; Pequignot E; Getz KD; Brogdon JL; Fesnak AD; Siegel DL; Davis MM; Bartoszek C; Lacey SF; Hexner EO; Chew A; Wertheim GB; Levine BL; June CH; Grupp SA; Maude SL
    J Clin Oncol; 2021 Sep; 39(27):3044-3055. PubMed ID: 34156874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term safety and activity of humanized CD19 chimeric antigen receptor T cells for children and young adults with relapsed/refractory acute lymphoblastic leukemia].
    Wang SY; Zhao LN; Cheng H; Shi M; Chen W; Qi KM; Sun C; Wang X; Cao J; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):557-561. PubMed ID: 36709132
    [No Abstract]   [Full Text] [Related]  

  • 20. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy.
    Zhang X; Yang J; Li J; Qiu L; Zhang J; Lu Y; Zhao YL; Jin D; Li J; Lu P
    Am J Hematol; 2023 Dec; 98(12):1898-1908. PubMed ID: 37740926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.